What You Should Know:
– OMNY Health, a healthcare ecosystem specializing in data partnerships, today announced the launch of its GLP-1 data network.
– The GLP-1 data network aims to democratize access to healthcare data and empower researchers, clinicians, and life sciences companies to gain valuable insights into GLP-1 therapies.
Addressing Data Gaps in GLP-1 Research
Despite the growing use of GLP-1 agonists, there remains a significant lack of comprehensive data on their effectiveness and long-term effects. OMNY Health’s GLP-1 data network addresses this gap by providing access to curated EMR data from over 645,000 patients. This data includes information on patient demographics, SDOH factors, and clinical outcomes, enabling researchers to conduct more robust studies.
Key Features of the GLP-1 Data Network:
- Diverse patient population: The network includes data from patients across various age ranges, race/ethnicity, regions, and provider/payer types.
- SDOH data: The network captures important SDOH factors, such as economic insecurity, food insecurity, and social isolation, which can significantly impact health outcomes.
- Pediatric data: The network includes valuable information on pediatric use of GLP-1 therapies, which is becoming increasingly important due to the FDA’s recent approval for this population.
Enabling Data-Driven Insights
OMNY Health’s GLP-1 data network empowers researchers and clinicians to:
- Diversify clinical trials: Access a broader patient population for more representative studies.
- Understand medication interactions: Gain insights into how GLP-1s interact with other medications.
- Strengthen treatment outcomes: Identify effective treatment strategies based on patient characteristics and SDOH factors.
The Importance of Data-Driven Decision Making
The availability of high-quality healthcare data is essential for driving innovation and improving patient outcomes. By providing access to a comprehensive GLP-1 data network, OMNY Health is helping to advance research and inform clinical decision-making in this important area.
“GLP-1 therapies are transforming the treatment landscape across multiple conditions beyond diabetes and obesity in profound ways. The systemic impact of these medications underlines the need for more comprehensive data to fully understand how these therapies affect patients as a whole,” said Dr. Mitesh Rao, CEO of OMNY Health. “By democratizing data partnerships between life sciences companies and health systems, we can enable more in-depth clinical research that will fuel healthcare innovation and revolutionize the potential impact of GLP-1’s for years to come.”
